Clinical trials: Motor Fluctuations
Parkinson's Disease
Efficacy of Ethnodyne Visio in Parkinson's Disease
ETHNODYNE VISIO is a food supplement composed of an innovative plant-based active ingredient acting alongside vitamin B2. It is proposed in patients with visual problems.
- Trial name
- ETHNOPARK (NCT02815800)
- Testing
- ETHNODYNE VISIO
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Strasbourg, France
Parkinson Disease
Pain in Parkinson's Disease With Motor Fluctuations.
Pain (spontaneous pain) is a fundamental non-motor symptom (NMS) of Parkinson's disease (PD) that is prevalent throughout the condition and often unrecognized and undertreated.
- Trial name
- PAINinPD (NCT03648671)
- Testing
- safinamide metansolfonato (12 weeks), rasagilina mesilato (12 weeks)
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- Universita di Verona
Parkinson's Disease
The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
A randomized, double blind, placebo-controlled study employing a mixed parallel group and fixed sequence cross-over design. Patients will be randomized to one of two treatment groups ('E2007' or 'Placebo') in a 1:1 ratio and…
- Trial name
- NCT00451633
- Testing
- E2007
- Where
- 5 sites in Germany, Italy
- Sponsor
- Eisai Inc.
Dyskinesias, Parkinson's Disease
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.
- Conditions
- Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
- Trial name
- NCT00360568
- Testing
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube
- Where
- 22 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson Disease
Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients
This is a phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa (LD/CD) vs.semi-continuous intra-oral administration of…
- Trial name
- LDCD-001 (NCT02763137)
- Testing
- Standard LD/CD, Semi continuous intra-oral administration of LD/CD
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- IRCCS San Raffaele Roma
Parkinson's Disease
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
An open-label randomized study to evaluate the Safety, Tolerability, and PK of Low and High single doses of ND0612 (i.e. LD/CD ratio 60/7.5 mg/mL and 60/14 mg/mL), as well as the combination with oral Entacapone (concomitant…
- Trial name
- NCT02096601
- Testing
- LD/CD SC solution, Entacapone
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- NeuroDerm Ltd.
Parkinson Disease (PD), Parkinson's Disease
Real-world Patient Experiences With Inbrija®
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing.
- Conditions
- Parkinson Disease (PD), Parkinson's Disease, Off Episodes of Parkinson Disease
- Trial name
- INHALE-PD (NCT07797790)
- Testing
- Levodopa inhalation powder
- Where
- 2 sites in Austria
- Volunteers
- 120 people
- Sponsor
- Merz Therapeutics GmbH
Parkinson's Disease
Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o.), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations…
- Trial name
- NCT01187966
- Testing
- Safinamide
- Volunteers
- 669 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
Lisuride Patch to Treat Parkinson's Disease
This study will evaluate the effectiveness of a skin patch formulation of the dopamine agonist Lisuride in controlling parkinsonian symptoms and dyskinesias (involuntary movements) caused by levodopa.
- Trial name
- NCT00089622
- Testing
- Intravenous Levodopa, Lisuride Transdermal System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease
Dopaminergic restauratIon by intraVEntriculaire Administration
Prospective monocentric randomized controlled open-label proof-of-concept study in cross-over of two 1-month periods and a long-term follow-up period not to exceed September 30, 2023, with 2 groups: Intracerebroventricular…
- Trial name
- DIVE (NCT04332276)
- Testing
- A-dopamine, optimized oral treatment
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Lille
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Parkinson's Disease
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
- Trial name
- NCT00203034
- Testing
- rasagiline mesylate, 1.0 mg rasagiline mesylate
- Where
- 4 sites in United States
- Volunteers
- 472 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
Parkinson Disease
Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study
Zonisamide (ZNS) (1,2-Benzisoxazole-3-methanesulfonamide) is an anti-epileptic drug. In three double blinded placebo controlled studies, ZNS- as an adjunctive treatment- showed beneficial effects on motor symptoms of PD with a…
- Trial name
- NCT04182399
- Testing
- Zonisamide Capsules
- Where
- 2 sites in Egypt
- Volunteers
- 69 people
- Sponsor
- Ain Shams University
Idiopathic Parkinsonism
Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health
This is a single-center, prospective observational study aiming to validate the Kinetikos Health App for fall risk assessment in PD patients undergoing dopaminergic medication adjustments.
- Trial name
- PD_FALLRISK (NCT07257393)
- Testing
- No Intervention: Observational Cohort
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Parkinson's Disease
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
- Trial name
- NCT00203164
- Testing
- rasagiline mesylate
- Where
- 6 sites in United States
- Volunteers
- 254 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated…
- Trial name
- NCT00148512
- Testing
- 1. Tesofensine (NS 2330)
- Where
- 50 sites in Austria, France and 4 more
- Volunteers
- 254 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. A total of 276 eligible Parkinson's disease participants with motor fluctuations will be enrolled and assigned to one of three…
- Trial name
- NCT07585565
- Testing
- GM1
- Volunteers
- 276 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00660387
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 14 sites in United States, New Zealand
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment.
- Trial name
- DARE2 (NCT07514858)
- Testing
- Lu AF28996
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- H. Lundbeck A/S